149 Medical

149 Medical is a private U.S. medical device company developing non-invasive neuro-monitoring technology for premature infants in the neonatal intensive care setting. Its lead product, NIRDS 1, is a continuous intracranial blood flow sensor designed to provide real-time monitoring and early warning signals associated with ventricular hemorrhage risk in very premature newborns. The company's technology is based on diffuse optical methods and is positioned as an alternative to intermittent transcranial Doppler-based monitoring. 149 Medical states that it holds an exclusive intellectual property license from Massachusetts General Hospital and is currently evaluating the technology clinically. The company appears focused on neonatal brain hemodynamics monitoring rather than therapeutics or drug development.